
Pfizer will now keep up to 650 jobs at its R&D site in Sandwich, Kent, according to news reports. The …
As a part of the ERA Consultancy Group, European Regulatory Solutions (ERS) specialise in offering consultancy services and regulatory advice …

GlaxoSmithKline has teamed up with gene silencing specialist Alnylam Pharmaceuticals in a project aimed at speeding up the production of …
Bosch Packaging Technology has decided to boost its presence in Asia with the construction of a second plant in the …
No new suitors come forward for PPD, Icon and Charles River report mixed Q3 results, plus updates from Cyprotex and …

Anti-microbial drug developers Destiny Pharma have appointed Dr David Roblin as its new medical director. Dr Roblin was formerly head …
Bristol-Myers Squibb has licensed one of its investigational oncology compounds, for the treatment of multiple solid tumours, to Singapore-based Aslan …

The FDA has approved Bayer/J&J’s Xarelto once-daily pill for stroke prevention in patients with an abnormal heart rhythm. The US …

Israeli drugmaker Teva Pharmaceutical could get an unexpected boost from an earlier-than-expected launch of its generic version of Pfizer’s cholesterol …

Steve Hobbs has joined Apodi’s senior management team as director of business and account development. Steve has over 30 years …
GE Healthcare and ex AstraZeneca Head of Global Regulatory Affairs, Graham Higson, will join NDA Group in January 2012 to …

US regulator the FDA has approved more drugs and at a faster rate than its European counterpart.A new report by …
A joint venture set up by GlaxoSmithKline and Pfizer is planning to start manufacturing in Russia thanks to a partnership …
Ketchum Pleon has accepted the International Consultancy of the Year award on behalf of the global firm Ketchum at the …

GlaxoSmithKline has agreed to pay $3 billion to settle US government investigations into the sales and marketing of diabetes drug …
Synergy Vision, the London-based medical communications agency, has hired Caroline Loder as a senior medical writer and Natalie Ferguson as a …

Sales growth at Teva was modest in Q3, rising 2% to $4.34 billion, with growth predominately coming from branded drugs.This …
Doctors in London are opposing a decision to switch HIV patients to a cheaper drug, saying it could harm patients. …
Richard Daniell has been appointed as managing director for Teva UK, and will be responsible for all Teva’s commercial activities …